MedTrace Logo

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

NCT07303712 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2025-12-26

No results posted yet for this study

Summary

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma (HCC)

Sponsors & Collaborators

  • Palo Alto Veterans Institute for Research

    lead OTHER

Principal Investigators

  • Sirish Kishore, MD · VA Palo Alto Health Care System

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2026-08-01
Completion
2026-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07303712 on ClinicalTrials.gov